Looking beyond traditional oncogenic pathways to break cancer resistance
Drug Target Review
SEPTEMBER 25, 2024
4 Another related and well described non-oncogene resistance mechanism is the histological transformation of EGFR-mutated non-small cell lung cancer (NSCLC) to small-cell lung cancer upon treatment with an EGFR inhibitor. This orally available small molecule binds to the bromodomain of CBP/p300 in a highly specific manner.
Let's personalize your content